Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: The activity and immune dynamics of PD-1 inhibition on high-risk pulmonary ground glass opacity lesions: insights from a single-arm, phase II trial

Fig. 2

Trial timeline, routine examinations, and outcome of the study. a After baseline information collection, enrolled patients received intravenous drip sintilimab 200 mg per 3 weeks for 4 cycles; blood sampling before every cycle (labeled as T1–T4) and chest CT scan after every 2 cycles. Biomarkers including T/B/NK-cell subpopulations, T-cell receptor (TCR), cytokines, and exosomal RNA, were monitored and compared between responders and non-responders. b The EGFR mutation status of resected or bioptic main lesion(s) of patients. c The objective response rate (ORR: 5.6%, 2/36) based on ITT lesions of patients. d The total response rate (13.9%, 5/36) considering two ITT lesions (pure-GGO or GGO-predominant) and three NITT lesions (pure-solid or solid-predominant). e The radiologic changes in chest CT of one patient who achieved significant response after sintilimab treatment. (A 78-years-old man with a smoking history; he has one ITT lesion manifesting as mixed GGO and with no NITT lesion)

Back to article page